logo
Plus   Neg
Share
Email

Sanofi's Investigational Iniparib, Otamixaban Fail To Meet Goals, Ends Programs

French drugmaker Sanofi (SNY,SNYNF.PK) Monday announced that Phase 3 studies of iniparib in squamous non-small cell lung cancer, and investigational anticoagulant otamixaban, an injectable factor Xa inhibitor, did not meet their respective primary endpoints. The firm has decided to terminate the internal development programs.

Following the study result, Sanofi will fully impair the intangible assets related to iniparib on the June 30, 2013 consolidated balance sheet. The related charge will have an estimated net impact of $285 million after tax on consolidated net income, or about 219 million euros. However, the company noted that the non-cash charge will have no impact on business net income.

According to the company, the randomized Phase 3 ECLIPSE trial of iniparib in squamous non-small cell lung cancer, or Sq NSCLC, failed to meet its primary endpoint. During the study, newly diagnosed, metastatic Sq NSCLC patients treated with iniparib plus chemotherapy did not achieve improvement in overall survival compared to patients who received chemotherapy alone.

The two arms showed no clinically meaningful differences in main safety parameters. The topline results of a Phase 2 study of iniparib in platinum-resistant ovarian cancer do not support further development of iniparib in this patient population, the company said.

Further, Sanofi stated that topline results of the completed Phase 3 study of investigational anticoagulant otamixaban showed that the study did not meet its primary endpoint of superiority over current therapy.

In the Treatment of non-ST elevation Acute coronary syndrome with otamixaban, or TAO study, due to efficacy lower than expected, otamixaban did not show superior benefit/risk to the combination of unfractionated heparin (UFH) +/- eptifibatide (a GP IIb/IIIa inhibitor) in non-ST elevation acute coronary syndrome patients planned for early invasive strategy.

The primary endpoint of the Phase 3 TAO study was the reduction of all-cause mortality or new heart attacks.

Sanofi stated that the results of both of the studies will be presented at upcoming scientific meetings and submitted for publication in peer-reviewed journals.

In Paris, Sanofi shares are currently trading at 82.65 euros, up 0.17 percent, on a volume of 1.51 million shares.

SNY closed Friday's regular trading at $53.09 on the NYSE. In the pre-market activity, the shares are currently up 0.60 percent.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Member of Congress have reportedly been told President Donald Trump's administration has reached an agreement to put Chinese telecom giant ZTE Corp. back in business. Reports from the New York Times and Reuters said the deal brokered by the Commerce Department would require ZTE to pay a substantial... Delta Air Lines will resume non-stop flights between the U.S. and India next year, almost a decade after it exited the Indian market. The airline said Thursday that its decision to resume non-stop flights from the U.S. to India follows agreements between the U.S. and the governments of the United Arab Emirates and Qatar to address the issue of government subsidies provided to state-owned carriers. Mortgage rates continued their upward trend this week and hit a seven-year high, even as housing demand remained robust. According to data released Thursday by mortgage finance provider Freddie Mac, the 30-year fixed-rate mortgage rose to 4.66 percent in the week ending May 24, from 4.61 percent in the prior week and 3.95 percent a year ago. This is also the highest level since May 5, 2011.
Follow RTT